The landscape of endocrine medicine has undergone a transformative shift following two major regulatory milestones announced by the U.S. Food and Drug Administration (FDA). In a move that expands the therapeutic options for both autoimmune and metabolic disorders, the FDA has granted accelerated approval to Sanofi’s Tzield (teplizumab-mzwv) for pediatric patients with newly diagnosed Stage 3 type 1 diabetes (T1D) and approved Ionis Pharmaceuticals’ Tryngolza (olezarsen) as a first-of-its-kind treatment for severe hypertriglyceridemia (sHTG). These developments represent significant progress in addressing unmet medical needs, providing clinicians with novel tools to preserve insulin production in children and prevent life-threatening pancreatitis in adults.
Tzield: A New Frontier in Preserving Beta Cell Function
On June 13, Sanofi confirmed that the FDA granted accelerated approval for Tzield to delay the decline of endogenous insulin production in pediatric patients aged eight to 17 years who have recently been diagnosed with Stage 3 T1D. This approval is particularly significant as it targets the autoimmune destruction of insulin-producing beta cells at a critical juncture—shortly after the clinical onset of the disease.
Type 1 diabetes is characterized by an immune system attack on the pancreas, traditionally categorized into three stages. Stage 1 involves the presence of two or more autoantibodies with normal blood sugar; Stage 2 involves autoantibodies and abnormal blood sugar (dysglycemia) but no outward symptoms; and Stage 3 is the point of clinical diagnosis, where symptoms such as excessive thirst, frequent urination, and weight loss become apparent. Tzield, a CD3-directed antibody, works by modulating the T-cells that attack beta cells, thereby slowing the progression of the disease.
The PROTECT Phase 3 Clinical Evidence
The regulatory decision was heavily influenced by data from the PROTECT Phase 3 study (NCT03875729). This trial focused on evaluating beta cell function through the measurement of C-peptide levels—a reliable biomarker for the body’s own insulin production. The study utilized a four-hour mixed-meal tolerance test to assess the area under the curve (AUC) for C-peptide levels.
The results demonstrated a statistically significant difference in the preservation of insulin production. Patients treated with Tzield showed a significantly slower decrease in mean C-peptide levels compared to the placebo group, with a difference in least-squares means of 0.13 pmol/mL (95% CI: 0.09-0.17; p<0.001). Beyond the primary endpoint, the broader clinical development program for Tzield involved more than 900 patients, providing a robust dataset for safety and efficacy.
Safety Considerations and Accelerated Approval Status
While Tzield offers a breakthrough in T1D management, it is not without risks. The most common adverse reactions reported during the PROTECT study included lymphopenia (reduced white blood cell count), vomiting, rash, leukopenia, diarrhea, and neutropenia. More serious concerns include cytokine release syndrome (CRS) and the potential for viral reactivation, particularly in immunocompromised patients.
Because Tzield was granted accelerated approval, its continued authorization for this specific indication may depend on the results of confirmatory trials. The BETA-PRESERVE Phase 3 study (NCT07088068) is currently underway to verify the long-term clinical benefits and further describe the drug’s impact on the disease trajectory.
Expanding Global Footprint and Regulatory History
The journey of teplizumab has been marked by several regulatory milestones. In April 2026, the FDA expanded its indication to include children as young as one year old for the delay of Stage 3 T1D onset in those with Stage 2 disease. Globally, the drug is gaining traction under various names and indications. In the European Union, it is marketed as Teizeild, and it has received approvals in the United Kingdom, China, Australia, Canada, Israel, Saudi Arabia, the UAE, Kuwait, Brazil, and Switzerland. Its status as a "breakthrough therapy" and "orphan drug" highlights its importance in treating a condition that affects approximately 64,000 newly diagnosed individuals in the U.S. annually.
Tryngolza: Redefining the Treatment of Severe Hypertriglyceridemia
On June 24, Ionis Pharmaceuticals announced that the FDA approved Tryngolza (olezarsen) as an adjunct to diet for adults with severe hypertriglyceridemia (sHTG), defined as triglyceride levels equal to or greater than 500 mg/dL. Tryngolza stands as the first and only approved therapy specifically designed to reduce both triglyceride levels and the risk of acute pancreatitis in this patient population.
Severe hypertriglyceridemia is a dangerous metabolic condition. When triglyceride levels exceed the 500 mg/dL threshold, the risk of acute pancreatitis—a painful and potentially fatal inflammation of the pancreas—increases dramatically. For many patients, traditional lipid-lowering therapies and strict dietary changes are insufficient to bring these levels into a safe range.
Efficacy Data from CORE and CORE2 Studies
The approval of Tryngolza was based on the pivotal Phase 3 CORE and CORE2 studies, the findings of which were published in The New England Journal of Medicine. These trials showcased the drug’s ability to achieve rapid and sustained triglyceride control.
Key data points from the studies include:
- Triglyceride Reduction: Patients treated with Tryngolza experienced fasting triglyceride reductions of up to 72% compared to placebo at the six-month mark, with these levels remaining stable through 12 months.
- Pancreatitis Risk: The therapy reduced acute pancreatitis events by a staggering 91%.
- Target Achievement: Approximately 86% of patients treated with Tryngolza achieved triglyceride levels below the critical 500 mg/dL threshold.
- Clinical Benefit: The "number needed to treat" (NNT) to prevent one episode of acute pancreatitis over a year was 20 for the general sHTG cohort. However, for high-risk patients with triglycerides above 880 mg/dL and a history of pancreatitis, the NNT was remarkably low at four.
Administration and Safety Profile
Tryngolza is an antisense oligonucleotide therapy that targets the mRNA responsible for producing apolipoprotein C-III (apoC-III), a key regulator of triglyceride metabolism. It is administered once monthly via a self-administered autoinjector in doses of either 50 mg or 80 mg.
The safety profile observed across the clinical programs was favorable. The most frequent side effects included injection site reactions and mild increases in liver enzymes. Unlike some older triglyceride-lowering medications, Tryngolza’s targeted approach appears to offer a more manageable tolerability profile for long-term use.
Perspectives from the Medical and Patient Communities
The arrival of these two therapies has been met with enthusiasm from healthcare providers and advocacy groups. For type 1 diabetes, Aaron J. Kowalski, PhD, CEO of Breakthrough T1D, emphasized that the approval of Tzield allows for a "proactive approach" to a disease that has historically been managed reactively with insulin replacement. By targeting the autoimmune attack itself, clinicians can potentially extend the "honeymoon phase" of the disease, during which the body still produces some insulin, making blood sugar management significantly easier and reducing the risk of long-term complications.
In the realm of lipidology, the sentiment is equally optimistic. Dr. Archna Bajaj of the University of Pennsylvania noted that Tryngolza addresses a "devastating" gap in care. For patients living with the constant fear of a pancreatitis attack, a monthly injection that provides nearly a 90% reduction in risk represents a paradigm shift. Emily Draud of the National Pancreas Foundation echoed this, stating that the therapy offers "hope for people who have been waiting for a new treatment to reduce the risk of acute pancreatitis."
Broader Implications for the Pharmaceutical Industry
The dual approvals of Tzield and Tryngolza underscore a broader trend in the pharmaceutical industry toward precision medicine and biological therapies. Sanofi’s commitment to Tzield, following its acquisition of Provention Bio, demonstrates a strategic focus on immunology and chronic disease modification. Meanwhile, Ionis Pharmaceuticals’ successful launch of Tryngolza marks the company’s transition into an independent commercial entity capable of bringing blockbuster treatments for prevalent metabolic diseases to market.
Furthermore, the use of accelerated approval pathways for Tzield reflects the FDA’s willingness to utilize surrogate endpoints—such as C-peptide levels—to speed up the delivery of medicines for serious conditions. This approach balances the need for rigorous safety data with the urgency of treating progressive diseases where early intervention is paramount.
Chronology of Availability and Support
Patients in the United States will have access to these treatments in the coming weeks. Tryngolza is expected to be available by July, with Ionis launching the "Ionis Every Step" program to assist with insurance navigation, financial aid, and injection training. Sanofi continues to roll out Tzield across various pediatric endocrinology centers, supported by clinical education initiatives to help providers identify eligible Stage 3 patients.
As the medical community integrates these therapies into standard care, the focus will shift to long-term monitoring. For Tzield, the results of the BETA-PRESERVE study will be vital in determining if the delay in insulin decline translates into a permanent alteration of the disease course. For Tryngolza, real-world evidence will further clarify its impact on reducing the burden of hospitalization associated with sHTG.
In conclusion, the FDA’s recent actions provide a significant boost to the treatment of endocrine disorders. By addressing the root causes of beta cell destruction in T1D and the lipid imbalances leading to pancreatitis, Tzield and Tryngolza offer a more hopeful future for thousands of patients navigating these complex health challenges.
